Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2

Yoshinori Kikuchi,Hideaki Shimada,Fumiyuki Yamasaki,Taku Yamashita,Koji Araki,Kohei Horimoto,Satoshi Yajima,Masakazu Yashiro,Keigo Yokoi,Haruhiko Cho,Takuya Ehira,Kazunari Nakahara,Hiroshi Yasuda,Kazutoshi Isobe,Tetsu Hayashida,Shingo Hatakeyama,Koichiro Akakura,Daisuke Aoki,Hiroyuki Nomura,Yuji Tada,Yuki Yoshimatsu,Hayato Miyachi,Chiaki Takebayashi,Ichiro Hanamura,Hiroyuki Takahashi
DOI: https://doi.org/10.1007/s10147-024-02497-0
2024-03-18
International Journal of Clinical Oncology
Abstract:In recent years, rapid advancement in gene/protein analysis technology has resulted in target molecule identification that may be useful in cancer treatment. Therefore, "Clinical Practice Guidelines for Molecular Tumor Marker, Second Edition" was published in Japan in September 2021. These guidelines were established to align the clinical usefulness of external diagnostic products with the evaluation criteria of the Pharmaceuticals and Medical Devices Agency. The guidelines were scoped for each tumor, and a clinical questionnaire was developed based on a serious clinical problem. This guideline was based on a careful review of the evidence obtained through a literature search, and recommendations were identified following the recommended grades of the Medical Information Network Distribution Services (Minds). Therefore, this guideline can be a tool for cancer treatment in clinical practice. We have already reported the review portion of "Clinical Practice Guidelines for Molecular Tumor Marker, Second Edition" as Part 1. Here, we present the English version of each part of the Clinical Practice Guidelines for Molecular Tumor Marker, Second Edition.
oncology
What problem does this paper attempt to address?